283. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
作者: Roland Veltkamp.;Eleni Korompoki.;Kirsten H Harvey.;Emily R Harvey.;Cornelia Fießler.;Uwe Malzahn.;Viktoria Rücker.;Joan Montaner.;Valeria Caso.;Igor Sibon.;Peter Ringleb.;Omid Halse.;Klemens Hügen.;Sabine Ullmann.;Carolin Schuhmann.;Gabriele Putz Todd.;Kirsten Haas.;Elena Palà.;Stéphanie Debette.;Morgane Lachaize.;Tim D'Aoust.;Christian Enzinger.;Stefan Ropele.;Simon Fandler-Höfler.;Melanie Haidegger.;Yanzhong Wang.;Hatem A Wafa.;Virginia Cancelloni.;Maria Giulia Mosconi.;Gregory Y H Lip.;Deirdre A Lane.;Walter E Haefeli.;Kathrin I Foerster.;Viktoria S Wurmbach.;Peter Brønnum Nielsen.;Karim Hajjar.;Patrick Müller.;Sven Poli.;Jan Purrucker.;Mona Laible.;Lucio D'Anna.;Yolanda Silva.;Reyes de Torres Chacon.;Patricia Martínez-Sánchez.;Marion Boulanger.;Bo Norrving.;Guillaume Paré.;Rolf Wachter.;George Ntaios.;Charles D A Wolfe.;Peter U Heuschmann.; .
来源: Lancet. 2025年405卷10482期927-936页
Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but the benefits and risks in survivors of intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage.
285. Feeding dystonia, chorea, psychosis, and self-mutilation in an African patient with neuroacanthocytosis syndrome.
作者: Maouly Fall.;Moussa Seck.;Alassane Mamadou Diop.;Jamil Kahwagi.;Grace Tsemo Yimta.;Allé Guéye.;Pedro Rodriguez Cruz.;Mie Rizig.
来源: Lancet. 2025年 286. A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
作者: John M Dennis.;Katherine G Young.;Pedro Cardoso.;Laura M Güdemann.;Andrew P McGovern.;Andrew Farmer.;Rury R Holman.;Naveed Sattar.;Trevelyan J McKinley.;Ewan R Pearson.;Angus G Jones.;Beverley M Shields.;Andrew T Hattersley.; .
来源: Lancet. 2025年405卷10480期701-714页
Data to support individualised choice of optimal glucose-lowering therapy are scarce for people with type 2 diabetes. We aimed to establish whether routinely available clinical features can be used to predict the relative glycaemic effectiveness of five glucose-lowering drug classes.
287. 20th anniversary of the WHO Framework Convention on Tobacco Control coming into force: time for a step change in ambition.
作者: Anna B Gilmore.;Cynthia Callard.;Deborah Sy.;Blanca A Llorente.;Upendra Bhojani.;Catherine O Egbe.;Stella Aguinaga Bialous.
来源: Lancet. 2025年405卷10480期677-681页 292. Human schistosomiasis.
作者: Dora Buonfrate.;Teresa Cristina A Ferrari.;Ayola Akim Adegnika.;J Russell Stothard.;Federico G Gobbi.
来源: Lancet. 2025年405卷10479期658-670页
Schistosomiasis is a neglected tropical disease caused by infection with blood flukes of the genus Schistosoma. Widely distributed in the Middle East, southeast Asia, Latin America, and (mostly) sub-Saharan Africa, schistosomiasis is acquired upon skin penetration of infective larvae released by freshwater snails. Acute infection might present with self-limiting hypersensitivity reactions (known as Katayama fever). Chronic infection typically leads to two main clinical patterns: intestinal or urogenital schistosomiasis, depending on the infecting species. Impairment of other body sites (eg, the CNS or respiratory tract) can occur. The intestinal form is characterised by abdominal pain and diarrhoea, with or without blood; complications are hepatic fibrosis, portal hypertension, splenomegaly, and variceal bleeding. The urogenital form is characterised by dysuria and haematuria; complications are renal failure and squamous-cell carcinoma of the bladder. Conventional diagnosis is based on egg detection in faeces or urine, although sensitivity might be low. Praziquantel is the first-line treatment, and it is also provided in preventive chemotherapy campaigns by mass drug administration to afflicted communities.
293. Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.
作者: Michel Michaelides.;Yannik Laich.;Sui Chien Wong.;Ngozi Oluonye.;Serena Zaman.;Neruban Kumaran.;Angelos Kalitzeos.;Harry Petrushkin.;Michalis Georgiou.;Vijay Tailor.;Marc Pabst.;Kim Staeubli.;Roni O Maimon-Mor.;Peter R Jones.;Steven H Scholte.;Anastasios Georgiadis.;Jacqueline van der Spuy.;Stuart Naylor.;Alexandria Forbes.;Tessa M Dekker.;Eugene R Arulmuthu.;Alexander J Smith.;Robin R Ali.;James W B Bainbridge.
来源: Lancet. 2025年405卷10479期648-657页
Retinal dystrophy caused by genetic deficiency of AIPL1 causes severe and rapidly progressive impairment of sight from birth. We sought to evaluate whether early intervention by gene supplementation therapy was safe and could improve outcomes in children with this condition.
294. Reflections on The Lancet's Commission on dementia prevention, intervention, and care - Authors' reply.
作者: Gill Livingston.;Sergi G Costafreda.;Mika Kivimäki.;Naaheed Mukadam.;Lon S Schneider.;Geir Selbæk.;Kokoro Shirai.;Andrew Sommerlad.
来源: Lancet. 2025年405卷10479期625-626页 |